Lifecore Biomedical, Inc. (NASDAQ:LFCR)
| Market Cap | 244.56M-8.8% |
| Revenue (ttm) | 122.64M-4.8% |
| Net Income | -37.28M+3.7% |
| EPS | -1.10+15.7% |
| Shares Out | 37.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,003,471 |
| Open | 6.52 |
| Previous Close | 4.20 |
| Day's Range | 6.42 - 6.65 |
| 52-Week Range | 3.63 - 8.98 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 6.39(-1.99%) |
| Earnings Date | Nov 3, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
$LFCR stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LFCR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LFCR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LFCR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LFCR Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| HA manufacturing | $18.61M | 54.48% |
| CDMO | $15.55M | 45.52% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LFCR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LFCR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LFCR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $3.67M |
| VXFVanguard Extended Market ETF | $1.94M |
| VTWOVanguard Russell 2000 ETF | $729.42K |
| VTWVVanguard Russell 2000 Value ETF | $110.63K |
| RSSLGlobal X - Russell 2000 ETF | $57.51K |
| VTHRVanguard Russell 3000 ETF | $8.58K |
Estimated from each fund’s disclosed top holdings × AUM
LFCR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LFCR’s recent data — informational, not investment advice
